Please directly call our main office to complete your appointment
Virtual Consultations
Book Appointment
850-407-2803
Menu
Type 2 diabetes can be a challenging condition to manage. Along with dietary changes and increased physical activity, many patients require medication to control elevated blood sugar levels.
In recent years, a class of injectable drugs called GLP-1 receptor agonists have emerged as an effective treatment option, providing the double benefit of lowering A1C while also promoting weight loss. But with multiple choices now available, including semaglutide, liraglutide and dulaglutide, how do you know which drug is right for you?
We’ll compare the key features of these three leading GLP-1 receptor agonists. We’ll look at how they work, effectiveness for glucose and weight control, safety profiles, dosing, and other factors that set them apart.
Let Dr. V and our staff help you discover the true beauty hiding within. Book your consultation with us today to learn more about your ideal cosmetic treatment.
First, a quick biology lesson. GLP-1 stands for glucagon-like peptide-1, which is a hormone released naturally in the body after eating. GLP-1 helps regulate blood sugar by stimulating insulin production and suppressing glucagon secretion. It also slows down digestion and increases feelings of fullness.
GLP-1 receptor agonists are injectable synthetic compounds designed to mimic these effects of naturally-occurring GLP-1. Three of the most commonly prescribed GLP-1 receptor agonists are:
These medications activate GLP-1 receptors, which triggers several responses:
The combined impact is lower blood glucose levels after meals, better long-term A1C control, and reduced appetite and calorie intake which supports weight loss.
While semaglutide, liraglutide and dulaglutide all work in a similar way by activating GLP-1 receptors, there are some notable differences that set them apart:
With A1C lowering capabilities superior to many other non-insulin medications, along with beneficial weight effects, GLP-1 receptor agonists have become popular options for controlling type 2 diabetes. But how do semaglutide, liraglutide and dulaglutide stack up against each other?
Here is a summary of key clinical trial findings on efficacy:
| Drug | Trial | A1C Reduction | Weight Loss |
| Semaglutide | SUSTAIN | 1.5-1.8% | 4.3-13.8 lbs |
| Liraglutide | LEAD | 0.8-1.5% | 2-7 lbs |
| Dulaglutide | AWARD | 1.1-1.6% | 2-3% body weight |
The SUSTAIN clinical trial program evaluated semaglutide in over 9,000 adults with type 2 diabetes. Key findings on A1C reduction and weight loss:
The LEAD trial series examined liraglutide in over 4,500 participants with type 2 diabetes. Notable efficacy data:
The AWARD program studied dulaglutide in 10 clinical trials with around 6,000 adults with type 2 diabetes. Key glycemic and weight findings:
In head-to-head studies, semaglutide 1mg has demonstrated greater A1C and weight reduction compared to 1.8mg of liraglutide and 1.5mg of dulaglutide. But all three drugs lead to significant improvements in glycemic control and body weight versus baseline and active comparators.
Beyond blood sugar lowering, GLP-1 receptor agonists have shown positive cardiovascular effects for patients with type 2 diabetes at high risk of heart disease.
Here are the key results from cardiovascular outcomes trials:
| Drug | Trial | Key Cardiovascular Results |
| Semaglutide | SUSTAIN 6 | 26% reduction in CV death, non-fatal MI or stroke |
| Liraglutide | LEADER | 13% reduction in same outcomes |
| Dulaglutide | REWIND | Non-inferior but no additional CV benefit |
The LEADER trial with liraglutide demonstrated a 13% reduction in the primary composite outcome of cardiovascular death, non-fatal MI or non-fatal stroke compared to placebo.
More recently, the SUSTAIN 6 study of semaglutide also showed cardiovascular benefits, with a 26% reduction in the same primary cardiovascular outcome versus placebo.
Dulaglutide was studied in the REWIND trial, where it showed non-inferiority but no additional reduction in major cardiovascular events compared to placebo.
Based on these findings, semaglutide and liraglutide are preferred if cardiovascular risk reduction is a major priority.
Along with controlling A1C, weight management is a key treatment goal for many people with type 2 diabetes. So what are the weight loss differences between semaglutide, liraglutide and dulaglutide?
In head-to-head clinical trials, semaglutide led to significantly greater weight reduction compared to both liraglutide and dulaglutide:
Additionally, the higher dose semaglutide 2.4mg used specifically for weight management was evaluated against liraglutide 3mg in the SCALE Obesity and Pre-Diabetes trial. Results showed:
This indicates that semaglutide has greater efficacy for weight control at both typical diabetes dosages and higher doses for obesity treatment compared to liraglutide and dulaglutide.
With comparison data showing differences in dosing, efficacy, side effects, and more, how should you and your doctor decide on semaglutide, liraglutide or dulaglutide? Here are some key factors to consider:
Frequency of dosing may fit better with certain lifestyles. Semaglutide and dulaglutide require only weekly injections, while liraglutide must be taken daily.
If A1C lowering is the primary goal, semaglutide provides the greatest reduction on average. For weight loss, semaglutide also looks most promising.
While all GLP-1 receptor agonists have similar side effects like nausea, semaglutide and liraglutide tend to have higher rates than dulaglutide. Liraglutide also carries a specific warning about gallbladder complications that the others do not. Those more prone to GI issues or gallstones may want to avoid liraglutide.
These medications can be used in mild-moderate renal impairment, but dose adjustments or restrictions apply for more severe kidney disease. Dulaglutide has the least renal effects, while liraglutide is contraindicated for end-stage renal disease.
The drug prices for GLP-1 agonists range from around $800-1500 per month without insurance. Coverage and out-of-pocket costs vary greatly between specific plans. Liraglutide tends to be the most affordable option.
If heart disease is a major concern, semaglutide or liraglutide may be preferred for their cardiovascular benefits. For obese patients, semaglutide also appears advantageous for greater weight reduction.
The choice between semaglutide, liraglutide and dulaglutide often comes down to the individual. Factors like lifestyle, side effect tolerance, administration, and cost all feed into the decision-making process between patient and provider. Shared decision making helps ensure the medication aligns with patient values and preferences.
When it comes to type 2 diabetes and obesity management, GLP-1 receptor agonists like semaglutide, liraglutide and dulaglutide can be highly effective. But for even better results, combine injectable medications with proven weight loss treatments from Dr. V Medical Aesthetics.
Our experienced medical team provides cutting-edge solutions to help you lose weight and improve your health. We offer semaglutide injections along with our signature Skinny Dip IV Therapy. This customized IV treatment contains a powerful blend of vitamins, amino acids and lipotropics to boost energy, burn fat and support your weight loss goals.
Dr. V Medical Aesthetics is ready to help you achieve your beauty goals. Contact us today to learn more about any of our services, and exactly what our team can do for you.
